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Abstract
Background: With improved childhood cancer cure rate, long term sequelae are becoming an
important factor of quality of life. Signs of cardiovascular disease are frequently found in long term
survivors of cancer. Cardiac damage may be related to irradiation and chemotherapy.
We have evaluated simultaneous influence of a series of independent variables on the late cardiac
damage in childhood cancer survivors in Slovenia and identified groups at the highest risk.
Methods:  211 long-term survivors of different childhood cancers, at least five years after
treatment were included in the study. The evaluation included history, physical examination,
electrocardiograpy, exercise testing and echocardiograpy. For analysis of risk factors, beside
univariate analysis, multivariate classification tree analysis statistical method was used.
Results and Conclusion: Patients treated latest, from 1989–98 are at highest risk for any injury
to the heart (73%). Among those treated earlier are at the highest risk those with Hodgkin's disease
treated with irradiation above 30 Gy and those treated for sarcoma. Among specific forms of injury,
patients treated with radiation to the heart area are at highest risk of injury to the valves. Patients
treated with large doses of anthracyclines or concomitantly with anthracyclines and alkylating
agents are at highest risk of systolic function defect and enlarged heart chambers. Those treated
with anthracyclines are at highest risk of diastolic function defect. The time period of the patient's
treatment is emerged as an important risk factor for injury of the heart.
Background
While agressive anticancer therapy in children is increas-
ingly successful in terms of survival, its adverse effects are
becoming more apparent. In childhood cancer the survi-
vor life expectancy is long and the impact of late sequelae
on their life quality is high [1]. These patients are one of
the largest risk groups for cardiovascular diseases, the car-
diac injury being related both to chemotherapy, especially
with anthracyclines, and irradiation [2,3]. The incidence
and severity of cardiomyopathy depend on the cumula-
tive dose of anthracyclines. The tolerance for anthracy-
clines is individual and cardiomyopathy may progress for
years after discontinuation of therapy. Cardiotoxicity may
be worsened by additional risk factors such as the patient
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age, female sex, type of cancer, radiation therapy to fields
that involve heart and concomitant exposure to cyclo-
phosphamide [2,4-10].
The purpose of the present study was: 1) to evaluate
simultaneous influence of a series of independent varia-
bles on late cardiac damage in childhood cancer survivors
in Slovenia using noninvasive evaluation methods; 2) to
identify groups of patients that are at the highest risk for
late cardiac damage.
Patients and Methods
Patients
In Slovenia, a single center serves as a national referral
center for all children with malignant disorders. After the
end of treatment, all children are followed at the center for
at least five years or until they are 18 years old. Later, they
are followed regularly at the outpatient Clinic for Late
Effects at the Institute of Oncology, Ljubljana. [11].
According to the Cancer Registry of Slovenia, between
1968 and 1998 1744 children were treated for malignant
diseases at the Oncology and Hematology Department of
the University Children's Hospital, Ljubljana and at the
Institute of Oncology, Ljubljana. Of the 874 survivors,
399 were regularly followed at the outpatients Clinic for
Late Effects. All were at least 18 years old and at least 5
years after treatment. 235 survivors were younger than 18
years old and less than five years after treatment of child-
hood cancer. We followed them at the University Chil-
dren Hospital. Of the remaining survivors who had
surgery only 95 were followed by surgeons or they refused
regullary follow up. There were 72 patients originally
from other parts of former Yugoslavia, who were not fol-
lowed after 1991 when Slovenia became independent
state.
The patients were systematically sent to the cardiologist
for evaluation, when they came to the outpatient Clinic
for late effects. There was no selection.
In 211 survivors complete cardiac evaluation was done.
They were treated for childhood cancer at the ages of two
month to 18 years (mean 9 years). Regarding the age at
diagnosis the patients were divided into three age groups
(0–6 years, 7–12 years, 13–18 years). According to the
type of malignancy, we divided patients into six groups:
patients with leukemia, Hodgkin disease, non-Hodgkin
lymphoma, sarcoma, brain tumors and other tumors. The
group of other tumors consisted of nephroblastoma, neu-
roblastoma, hepatoblastoma, retinoblastoma and carci-
nomas. The treatment modalities were surgery,
chemotherapy, radiotherapy or any combination of those.
Due to the considerable differences in treatment during
different time periods, three groups of patients were
formed: from 1968–1978, 1979–1988, 1989–1998. The
duration of follow-up ranged from 5 to 32 years (mean 16
years).
See Additional file 1.
Cardiac evaluation
Cardiac evaluation included history, physical examina-
tion, electrocardiography (ECG), exercise testing using a
bicycle ergometer, and echocardiography. New York
Heart Association (NYHA) functional classification and
therapeutic classification applied to dyspnea were used.
A supine standard 12-lead ECG was performed.
A submaximal exercise tolerance test was performed using
a bicycle ergometer. Every 3 minutes the workload was
increased by 30-, 40-, or 50-W increments as determined
by gender and weight. The exercise testing was stopped
when the expected heart rate at 75% aerobic efficiency
(according to age, sex, and body weight) was reached or
due to symptoms suggestive of cardiovascular disorder.
During exercise and recovery, ECG, blood pressure and
heart rate were measured every 3 minutes. The achieved
working capacity was expressed both in absolute terms
and as a percentage of predicted values according to stand-
ards adjusted for age, sex and body weight. The echocardi-
ographic evaluation consisted of M-mode, two-
dimensional, and pulsed, continuous-wave and color
Doppler echocardiography. To evaluate the left ventricle,
the following parameters were measured: left ventricular
end-diastolic and end-systolic dimension and septal and
posterior wall thickness at end diastole. The anterior-pos-
terior and superior-inferior diameter of the left atrium
were measured from apical 4-chamber view using two-
dimensional echocardiography. A color Doppler echocar-
diography was used to evaluate valvular function. The
systolic function of the left ventricle was defined by two
parameters: the ejection fraction (EF) and the fractional
shortening (FS). The diastolic function of the left ventricle
was assessed with pulsed Doppler echocardiography.
Peak early mitral blood flow velocity (E) and peak mitral
velocity during atrial contraction (A) were measured. The
E/A ratio and deceleration time of peak early blood flow
velocity (DT) and isovolumic relaxation time (IVRT) were
determined. The velocity profile in the right upper pulmo-
nary vein was analysed: an anterograde velocity recorded
during ventricular systole (wave S); the anterograde
diastolic wave (wave D); and the reverse pulmonary
venous flow during atrial contraction (wave A).
Statistical methods
The following parameters for univariate analysis of vari-
ous risk factors on cardiac damage were used: age at diag-
nosis, sex, type of malignancy, time period of treatment,BMC Cancer 2008, 8:141 http://www.biomedcentral.com/1471-2407/8/141
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type of treatment, cumulative dose of anthracyclines, con-
comitant treatment with antracyclines and alkylating
agents, dose of chest irradiation and duration of follow
up.
The chi-square test was used. P-values of < 0,05 were con-
sidered statistically significant.
Classification tree analysis
Classification tree analysis is a method of multivariate
analysis that allows to study of simultaneous influence of
a series of independent variables on one dependent varia-
ble [12]. The analysis is performed by successive divisions
of the original group of cases into pairs of subgroups,
where each division is based on the value of a single inde-
pendent variable. The variable that produces the purest
pair of case subgroups is chosen for a division (division
being often referred to as a split). A purity of a case group
is measured as a fraction of cases with the same value of
the dependent variable: a completely pure group contains
cases that have the same outcome. Each of the subgroups
in the pair becomes a parent group in the next step of the
analysis and is further divided in the same way. The divi-
sion of cases stops when the group of cases is completely
pure or when it contains less than operator-defined mini-
mal number of cases. In our study, the C4.5 [13] program
for building classification trees was used. C4.5 allows the
setting of several parameters that influence branching and
quality of the final classification tree: most notably there
is one parameter that determines the smallest number of
cases to be included in a single group (mentioned already
above in table 1), and another parameter that determines
the degree of post-pruning performed. For details please
refer to the description in [13]. The optimal values of
these parameters were determined using a standard cross-
validation method [14-16]. The usual performance meas-
ure for classification trees is the accuracy of the tree when
predicting the outcome (the value of the dependent varia-
ble) on samples not seen during the process of tree build-
ing.
Note finally, that since we use an alternative performance
criterion, the classification tree obtained the cross-valida-
tion procedure outlined above is not expected to provide
accurate classification of cases into cardiac damage and
non-cardiac damage classes. Instead of using the tree as an
accurate predictor, we were interested in analyzing the tree
structure and identyfing the risk group where incidence of
cardiac damage is significantly higher than the one
observed in the population of 211 patients included in
the study.
Multivariate analysis with classification tree was not done
when specific abnormalities were found in less than ten
percent of examinated childhood cancer survivors.
The study was performed in compliance with the Helsinki
Declaration with the approval N° 38/11/96 of National
Medical Ethics Committee of Slovenia. All the patients
gave their approval for the parcipitation in Late Effect
Study.
Results
Among 211 childhood cancer survivors tested for cardiac
damage 38 (18%) complained of fatigue, shortness of
breath on exercise, palpitations and nonspecific chest
pain on exercise (NYHA class 2). Twenty-two patients
(4,3%) had high blood pressure.
Standard Twelve-Lead Electrocardiography
In nineteen (9,2%) survivors the following abnormalities
of resting ECG were detected: ST-T wave changes, prolon-
gation of interval QT, right bundle branch block,
supraventricular and ventricular premature complexes
and supraventricular tachycardia. Electrocardiographic
abnormalities were more frequent in patients who were
treated with anthracyclines, in particular with high cumu-
lative dose of anthracyclines, although this difference was
not statistically significant (p = 0.08)
Exercise testing
An Exercise testing was performed in 179 patients (85%).
In nineteen (10%), the testing was ended due to fatigue
and weakness, dyspnea and nonspecific chest pain. In one
hundred and two patients (57%) the heart rate increased
excessively. The exercise tolerance was below the pre-
dicted values in eighty-three patients (46%). In 62% of
these patients ECG and echocardiography abnormalities
were found.
In only one patient signs of myocardial ishaemia were
detected during testing.
The type of malignancy influenced significantly on dimin-
ished exercise tolerance in univariate analysis (p =
0.0001). Patients who were treated for brain tumors were
at the highest risk for diminished exercise tolerance.
Echocardiography
Size of heart chambers
Thirteen patients (6,9%) had dilated left heart chambers.
The cumulative dose of anthracyclines (p = 0.0034) and
concomitant treatment with anthracyclines and alkylating
agents (p = 0.049) significantly influenced their dimen-
sions.
Heart valves and pericardium
In 48 patients (23%) structural or functional damage to
the heart valves was found. Most had asymptomatic
mitral and tricuspidal valvular thickening with or without
mild regurgitation or stenosis. Five patients had asympto-BMC Cancer 2008, 8:141 http://www.biomedcentral.com/1471-2407/8/141
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matic moderate regurgitation. There were no patients with
severe valvar regurgitation or severe stenosis.
The type of malignancy (p = 0.0006), radiation therapy (p
= 0,00001) and concomitant treatment with radiotherapy
and anthracyclines (p = 0,037) influenced significantly
valvular heart disease in univariate analysis.
In seven patients (3,3%) echocardiographic changes con-
sistent with thickened pericardium were found.
Left ventricular systolic function
A left ventricular systolic dysfunction was found in 15
patients (7,1%). The exercise tolerance was below the pre-
dicted value in 5 patients (33%) with systolic dysfunction.
In one of them, myocardial ischemia was detected during
exercise testing.
Nine patients with systolic dysfunction (9/15) had dilated
left heart chambers.
Concomitant treatment with anthracyclines and alkylat-
ing agents significantly influenced the left ventricular
systolic function (p = 0,05).
Left ventricular diastolic function
A left ventricular diastolic dysfunction was detected in 59
patients (28,6%). IVRT was measured in 186 patients, 33
of whom had prolonged IVRT. E and A velocities were
measured in 199 patients. Thirty-four patients had abnor-
mal ratio E/A. Eight patients had both parameters abnor-
mal. A pattern of abnormal relaxation was found in 25
patients and »pseudonormalisation« in nine patients. The
deceleration time of the early wave E was pathological in
72 patients.
Exercise tolerance was below the predicted values in 28
patients (57%) with diastolic dysfunction.
Chemotherapy with anthracyclines (p = 0,013) and ther-
apy with irradiation (p = 0,014) was significant for abnor-
mal ratio E/A but not the prolonged IVRT.
See Additional file 2.
Multivariate analysis
Decision trees multivariate analysis was performed step-
wise analysing independent influence of risk factors on
different levels of cardiac damage. First we analysed the
impact of above mentioned independent variables on
heart valves damage in 208 patients. We used a 10 fold
cross validation test mode. The variable that gave the first
division was radiotherapy with the heart involved in the
field, showing just 14% of patients without radiotherapy
against 47% in the radiotherapy group who had heart
valve disease. Further division in the radiotherapy group
revealed that the patients who were not treated with
anthracycline had more valvular damage than those
treated with it.
See Figure 1.
The next analyzed outcome was diastolic dysfunction in
59 patients. The variables were the same. The surogate
marker for diastolic dysfunction was IVRT. The resulting
tree has just one branching and shows that anthracycline
treatment was the most important factor for diastolic dys-
function regardless of the cumulative dose.
See Figure 2.
The last decision tree analysis was performed using the
same variables and the overall cardiotoxicity as the end-
point in 211 patients. Cardiotoxicty as a defined end-
point was any abnormality in the structure and/or func-
tion of the heart found by our test battery. The resulting
tree was highly branched. The period of treatment pro-
duced the first division showing that patients treated in
the period from 1989 to 1998 were at the highest risk for
cardiotoxicity.
Clasification tree for risk of heart valve disease after treat- ment of childhood cancer Figure 1
Clasification tree for risk of heart valve disease after 
treatment of childhood cancer.BMC Cancer 2008, 8:141 http://www.biomedcentral.com/1471-2407/8/141
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See Figure 3.
For the patients treated in the period from 1968–88 there
was further branching according to type of neoplasm.
Patients treated for sarcoma and non-Hodgkin disease
were the most affected groups having cardiotoxicity in
87% and 69% respectively. Among patients with Hodgkin
disease, those who were treated with irradiation dose
above 30 Gy were at highest risk. The group with lowest
risk were patients treated for brain tumor (20%).
Discussion
In recent years, cardiotoxicity after cancer treatment has
been a subject of many papers and comprehensive reviews
[3,10,17-20]. Most of them studied the effect of anthracy-
cline treatment on cardiac function [4,5,7,21-23]. In
many anthracyclines studies, patients treated with irradia-
tion have been excluded. Conversely, in many studies
reporting cardiac side effect of irradiation, the patients
have not received anthracyclines. In this study of 211
long-term childhood cancer survivors, we have found car-
diac damage of various types in more than half of studied
subjects. Our study group was heterogenuos according to
the type of cancer treated. On the other hand it was a very
homogenuos population wise. Moreover, patients were
treated and followed-up in a single centre. The statistical
method we have used enabeled us to study simultaneous
influence of a series of independent variables, such as
chemotherapy and radiotherapy, on different aspects of
late cardiac sequelae. Our results indicate that different
modes of anticancer treatment cause different types of
damage of cardiac structure and/or function.
According to our results the time period of the patient's
treatment emerged as an important risk factor for injury of
the heart. Our finding of multivariate analysis show that
patients treated latest, in the years 1989–98 are at highest
risk for any injury of the heart. These patients were treated
with intensive multiagent chemotherapy. They received
larger cumulative doses of anthracycline (more than 200
mg/m2) and they received more agressive chemotherapy.
They were treated often concomitantly with anthracycline
and alkylating agents.
See Additional file 3.
It is reported by some authors in similar studies that
female gender is a predictor for cardiac damage. We were
not able to confirm this observation with the results of our
study.
All our patients with pericardial lesions were asympto-
matic. Minor and localised thickening of pericardium has
also been observed by others [8,17,24]. The frequency of
reported clinically apparent radiation pericarditis follow-
ing irradiation was 0% to 2,4% [9,24].
The thickening of the heart valves, mostly mitral and aor-
tic, was a frequent finding after radiation therapy, increas-
ing with total doses higher than 30 Gy (23% of all
patients). Similar findings were reported by Glanzmann
[8,9,24]. In most cases, the valve abnormalities were slight
and without haemodynamic consequences. Patients
treated with irradiation and without anthracyclines are at
the highest risk for heart valve disease which occured in
75% of patients. A possible explanation for this could be
that in the time period higher doses of irradiation were
used (> 30 Gy), older radiation therapy techniques were
available and less effective shielding was used. After a
longer observation time (> 20 years) valvular dysfunction
have been observed in more patients in our study (30%)
than in patients with shorter observation time (< 20 years)
although the difference was not statistically significant. In
a similar study, valvular heart disease increased from 20%
5 years after irradiation to 60% after 18 years [8]. Patients
have been treated with mediastinal radiotherapy and
chemotherapy.
Patients in our study treated with a large cumulative dose
of anthracycline and those treated concomitantly with
anthracyclines and alkylating agents were at the highest
risk for systolic dysfunction and enlarged left heart cham-
bers. These results are in concordance with the results
reported by other authors [3,5,21,26,27]. However, our
cumulative dose at which myocardial toxicity was
reported was lower than the doses at which myocardial
toxicity was reported by other authors [3,5,10,21]. The
group of patients treated with radiotherapy alone seemed
Decision tree for risk of diastolic dysfunction Figure 2
Decision tree for risk of diastolic dysfunction.BMC Cancer 2008, 8:141 http://www.biomedcentral.com/1471-2407/8/141
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to have tolerated the therapy better than the anthracycline
group in terms of myocardial function [8,17].
However no statistically significant relationship between
the anthracycline dose and abnormal diastolic function
was observed. This is in concordance with Sorenson et al
[28]. The individual patients may have a lower treshold
and developed cardiotoxicity at a dose of anthracycline
less than 100 mg/m2  [29,30]. Abnormalities of active
myocardial relaxation may occur according to the relative
importance of myocyte loss, residual myocyte hypertro-
phy and interstitial fibrosis in each individual [31,32].
The results of our study showed that exercise tolerance
was below the predicted values in almost one half of all
survivors (46%). Deterioration of cardiac exercise toler-
ance is a common finding in children after anticancer
chemotherapy, but in most cases it is subclinical [33]. The
electrocardiogram and echocardiography revealed abnor-
malities in more than half of these patients (62%). They
could be classified as chronic heart failure class 1 (NYHA).
In multivariance analysis, no specific treatment related
factor was associated with lower exercise tolerance. Simi-
lar findings were reported by other studies [33]. This
would explain the low level of exercise tolerance due to
malignant disease and its treatment in childhood. Physi-
cal inactivity and obesity in more than one third of our
patients may have contribute to worsening of the cardiac
function in later years.
We have confirmed the frequent occurence of ECG abnor-
malities, including changes of ST-T wave, prolongation of
QT interval, AV block, right bundle branch block,
Decision tree for overall cardiac damage after treatment of childhood cancer Figure 3
Decision tree for overall cardiac damage after treatment of childhood cancer.BMC Cancer 2008, 8:141 http://www.biomedcentral.com/1471-2407/8/141
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supraventricular and ventricular premature complexes,
supraventricular tachycardia. However, all abnormalities
were of little clinical significance. We did not find any sig-
nificant relation between ECG changes and type of anti-
cancer treatment although 17 out of 19 patients with
abnormalities in ECG were treated with anthracyclines.
Neither have we found a relation between abnormal
systolic or diastolic function and findings on standard
ECG.
The results are in concordance with the results reported by
other authors [35]. Using a multivariate method of deci-
sion trees, we were able to confirm the observation
reported by other authors studying cardiac sequelae after
treatment of childhood cancer. We have at the same time
confirmed the results obtained by decision tree analysis
with univariate statistical methods.
Conclusion
￿ The frequency of late cardiac effects after childhood can-
cer treatment in the present study was 53%. One of the
patients died of sudden cardiac death 25 years after radia-
tion therapy for Hodgkin's disease. The autopsy revealed
myocardial fibrosis.
￿ Patients treated with large cumulative doses of anthracy-
cline and those treated concomitantly with anthracyclines
and alkylating agents are at the highest risk for systolic
dysfunction and enlarged left heart chambers.
￿ Patients treated with anthracyclines are at the highest
risk for diastolic dysfunction.
￿ Patients treated with incidental irradiation of the heart
are at the highest risk for heart valves disease.
Our findings demonstrate that the highest risk for any
type of cardiac damage after treatment of childhood can-
cer is present in:
￿ All patients treated latest, in the years from 1989–98
(73%).
￿ Among those treated earlier from (1968–78, 1979–88)
for Hodgkin's lymphoma treated with irradiation above
30 Gy.
￿ Patients with sarcoma who were treated in the years
from 1968–88.
Conflict of interest statement
The authors declare that they have no competing interests.
Authors' contributions
All authors read and approved the final manuscript. VV
caried out the patient recruitment, acquisition and inter-
pretation of the data. VV and JJ also drafted the manu-
script. UM performed the cardiac evaluation. DD
performed the decision tree analysis. BJ is a leader of Late
effect study group. She and CK participated in the design
of the study, carried out the patient recruitment and gave
final approval of the version to be published.
Additional material
Acknowledgements
The study was partially supported by grant J3-8924-302-97 of the Ministry 
of Higher Education, Science and Technology of Republic Slovenia.
References
1. Schwartz CL: Late effects of treatment in long-term survivors
of cancer.  Cancer Treat Rev 1995, 21:355-66.
2. Truesdell S, Schwarts CL, Clark E, et al.: Cardiovascular effect of
cancer therapy.  In Survivors of childhood cancer Edited by: Schwarts
CL, Hobbie WL, Constine LS. Mosby; 1994:159-75. 
3. Krischer JP, Epstein S, Cuthbertson DD, Goorin A, et al.: Clinical
cardiotoxicity following anthracycline treatment for child-
hood cancer: The pediatric oncology group experience.  J Clin
Oncol 1997, 15:1544-1552.
4. Steinherz LJ, Steinherz PG, Heller G: Anthracycline-related car-
diac damage.  In Cardiac toxicity after treatment for childhood cancer
Edited by: Bricker JT, Green DM, D' Angio GJ. New York: Wiley-Liss;
1993:63-72. 
5. Lipschultz SE, Colan SD, Gelber RD, Perez Atayde AR, et al.: Late
cardiac effects of doxorubicin therapy for acute lymphoblas-
tic leukemia in childhood.  N Engl J Med 1991, 324:808-15.
6. Schimmel KJM, Richel DJ, Brink RBA van den, Guchelaar HJ: Cardio-
toxicity of cytotoxic drugs.  Cancer Treat Rev 2004, 30:181-191.
7. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy.  N
Engl J Med 1998, 339:900-05.
Additional file 1
Table 1
Description and values of the independent variables and the dependent 
variable (last row-cardiac damage) used for univariate and mutivariate 
analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-8-141-S1.doc]
Additional file 2
Table 2
Factors significantly associated with abnormalities on cardiac evaluation 
(univariate analysis).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-8-141-S2.doc]
Additional file 3
Table 3
Treatment during three different time intervals.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-8-141-S3.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:141 http://www.biomedcentral.com/1471-2407/8/141
Page 8 of 8
(page number not for citation purposes)
8. Glanzmann Ch, Huguenin P, Lutolf UM, Maire R, et al.:  Cardiac
lesions after mediastinal irradiation for Hodgkin' s disease.
Radiother Oncol 1994, 30:43-54.
9. Green DM, Gingell RL, Pearce J, Panahan AM, et al.: The effect of
mediastinal irradiation on cardiac function of patients
treated during childhood and adolescence for Hodgkin's dis-
ease.  J Clin Oncol 1987, 5:239-245.
10. Nyson K, Holm K, Lipsitz SR, Mone SM, et al.:  Relationship
between cumulative anthracycline dose and late cardiotox-
icity in childhood acute lymphoblastic leukemia.  J Clin Oncol
1998, 16:545-550.
11. Jereb B: Model for long-term follow up of survivors of child-
hood cancer.  Med Pediatr Oncol 2000, 34:256-258.
12. Jereb B, Eklund G: Factor influencing the cure rate in nephrob-
lastoma.  Acta Radiologica Therapy Physics Biology 1973, 12:84-106.
13. Cancer Registration: Principles and methods.  Volume 95.
Lyon: IACRSci; 1991. 
14. Quinlan JR: C4.5: Programs for Machine Learning.  San Mateo,
CA: Morgan Kaufmann; 1993. 
15. Jazbec J, Todorovski L, Jereb B: Classification tree analysis of sec-
ond neoplasms in survivors of childhood cancer.  BMC Cancer
2007, 7:27.
16. Macedoni-Lukšiè M, Jereb B, Todorovski L: Long-term sequelae in
children treated for brain tumors: impairments, disability
amd handicap.  Pediatr Hematol and Oncol 2003, 20:89-101.
17. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mor-
tality from heart disease after treatment of Hodgkin' s dis-
ease.  Jama 1993, 270:1949-1955.
18. Pihkala J, Saarinen UM, Lundstrom U, Virtanen K, et al.: Myocardial
function in children and adolescents after therapy with
anthracyclines and chest irradiation.  Eur J Cancer 1996,
32A:97-103.
19. Leandro J, Dyck J, Poppe D, Shore R, et al.: Cardiac dysfunction
late after cardiotoxic therapy for childhood cancer.  Am J Car-
diol 1994, 74:1152-1156.
20. Bossi G, Lanzarini L, Laudisa ML, Klersy C, et al.:  Echocardio-
graphic evaluation of patients cured of childhood cancer: A
single center study of 117 subjects who received anthracy-
clines.  Med Pediatr Oncol 2001, 36:593-600.
21. Shan K, Lincoff M, Young JB: Anthracycline-induced cardiotoxic-
ity.  Ann Intern Med 1996, 125:47-58.
22. Pinarli FG, Oguz A, Sedef Tunaoglu F, Karadeniz C, et al.: Late car-
diac evaluation of children with solid tumors after antracy-
cline chemotherapy.  Pediatr Blood Cancer 2005, 44:370-377.
23. Marx M, Langer T, Graf N, Hausdorf G, et al.: Multicentre analysis
of anthracycline-induced cardiotoxicity in children following
treatment according to the nephroblastoma studies SIOP
No 9/GPOH and SIOP 93-01/GPOH.  Med Pediatr Oncol 2002,
39:18-24.
24. Pohjola-Sintonen S, Totterman KJ, Salmo M, Siltanen P: Late cardiac
effect of mediastinal radiotherapy in patients with Hodgkin's
disease.  Cancer 1987, 60:31-37.
25. Goorin AM, Chauvenet AR, Perez Atayde AR, Cruz J, et al.: Initial
congestive heart failure, six to ten years after doxorubicin
chemotherapy for childhood cancer.  J Pediatr 1990, 116:144-7.
26. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, et al.: Cardiac tox-
icity 4 to 20 years after completing anthracycline therapy.
Jama 1991, 266:1672.
27. Velenšek-Prestor V, Rakovec P, Koželj M, Jereb B: Late cardiac
damage of anthracycline therapy for acute lymphoblastic
leukemia.  Pediatr Hemat Oncol 2000, 17:527-540.
28. Sorensen K, Levitt G, Bull C, Chessells J, et al.: Anthracycline dose
in childhood acute lymphoblastic leukemia: issues of early
survival versus late cardiotoxicity.  J Clin Oncol 1997, 15:61-8.
29. Sung RYT, Huang GY, Shing SJ, Oppenheimer CK, et al.: Echocardi-
ographic evaluation of cardiac function in paediatric oncol-
ogy patients treated with or without antracycline.  Int J of
Cardiol 1997, 60:239-248.
30. Bu Lock FA, Mott MG, Oakhill A, Martin RP: Early identification of
anthracycline cardiomyopathy: possibilities and implica-
tions.  Arch Dis Child 1996, 75:416-422.
31. Cottin Y, Touzery C, Coudert B, Gilles A, et al.: Impairment of
diastolic function during short-term anthracycline chemo-
therapy.  Br Heart J 1995, 73:61-64.
32. Bu'Lock FA, Mott MG, Oakhill A, Martin RP: Left ventricular
diastolic function after anthracycline chemotherapy in child-
hood: relation with systolic function, symptoms, and patho-
physiology.  Br Heart J 1995, 73:340-50.
33. Labovitz AJ, Pearson AC: Evaluation of left ventricular diastolic
function: clinical relevance and recent Doppler echocardio-
graphic insights.  Am Heart J 1987, 114:836-49.
34. Turner-Gomes SO, Lands CL, Halton J, Hannig MR, et al.: Cardiores-
piratory status after treatment for acute lymphoblastic
leukemia.  Med Pediatr Oncol 1996, 26:160-65.
35. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, et al.: Electrocardi-
ographic changes and arrhythmias after cancer therapy in
children and young adults.  Am J Cardiol 1992, 70:73-7.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/141/pre
pub